Grass pollen allergy is an allergy caused by the pollen that comes from grasses and it tends to start growing in the spring. The symptoms associated with the grass pollen allergy includes cough, runny nose and itchy eyes. Dry winds, unmowed lawn and certain foods such as melons, oranges, peaches, celery and tomatoes can make the allergy worse. According to data published by the Asthma and Allergy Foundation of America, allergic conditions are the most common health issues affecting children in the U.S. Biomay AG is in the process of developing BM32 for the treatment of grass pollen allergy. BM32 is the peptide carrier fusion allergy vaccine and has completed Phase IIb of clinical development and is ready for Phase III pivotal trials. Some of the companies having a pipeline of grass pollen allergy include ASIT Biotech, HAL Allergy Group and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities, including information about clinical results, designations, collaborations, licencing, grants, technology and others.